Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RECURSION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/13/2021 | 07:58am EDT

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2021, Recursion Pharmaceuticals, Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information pursuant to Item 2.02 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number              Description
                              Press release issued by Recursion Pharmaceuticals, Inc. dated
99.1                            A    ugust     1    3    , 2021
                            Cover Page Interactive Data File (embedded within the Inline XBRL
104                         document)

© Edgar Online, source Glimpses

All news about RECURSION PHARMACEUTICALS, INC.
10/13Certain Options of Recursion Pharmaceuticals, Inc. are subject to a Lock-Up Agreement E..
CI
10/13Certain Warrants of Recursion Pharmaceuticals, Inc. are subject to a Lock-Up Agreement ..
CI
10/13Certain Class B Common Stock of Recursion Pharmaceuticals, Inc. are subject to a Lock-U..
CI
10/07Health Care Stocks Ending Near Top of Thursday Leaderboard
MT
10/07Recursion Pharmaceuticals Shares Rise 8% After Fast Track Designation
DJ
10/07RECURSION PHARMACEUTICALS : Says US FDA Grants REC-2282 Fast Track Designation for Potenti..
MT
10/07RECURSION PHARMACEUTICALS : is Granted FDA Fast Track Designation for REC-2282 for the Pot..
PU
10/07RECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
10/07RECURSION : is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment..
PR
10/07Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatmen..
CI
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 10,5 M - -
Net income 2021 -164 M - -
Net cash 2021 391 M - -
P/E ratio 2021 -14,8x
Yield 2021 -
Capitalization 3 208 M 3 208 M -
EV / Sales 2021 268x
EV / Sales 2022 275x
Nbr of Employees 270
Free-Float 77,6%
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 19,04 $
Average target price 33,17 $
Spread / Average Target 74,2%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson President & Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.0.00%3 208
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156